Psychiatry Medical News about schizophrenia

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Omega-3 fatty acids for bipolar disorder

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Clinical and resource-use outcomes of risperidone long-acting injection in recent and long-term diagnosed schizophrenia patients: results from a multinational electronic registry
Current Medical Research and Opinion, 07/16/09

Olivares JM et al. - Treatment with RLAI is associated with improved outcomes in recently diagnosed and chronic patients. However, the magnitude of improvement was higher in recently diagnosed patients.

Methods

The electronic Schizophrenia Treatment Adherence Registry (e-STAR) is an observational study of patients with schizophrenia who start treatment with RLAI.
Data were recorded at baseline, retrospectively for the 12 months prior to baseline, and prospectively every 3 months for 24 months.
Data on patients with a defined length of diagnosis were pooled from eight countries.
Clinical Global Impression of Illness Severity (CGI-S), Global Assessment of Functioning (GAF) scores, and hospitalization data were key outcomes.

Results

The magnitude of improvement in CGI-S scores was greater in the recent versus long-term diagnosis group.
There were parallel improvements in GAF scores.
The decline in the proportion of patients hospitalized from the retrospective to the prospective period was greater in the recent versus long-term diagnosis group .
This was also true for the number of hospital and length of stay at 12 months.
Common adverse events in both groups included psychiatric, gastrointestinal, musculoskeletal and reproductive system and breast disorders.

<< Previous
The CATIE and CUtLASS Studies in Schizophrenia: Results and...

Next >>
Zonisamide: In Parkinsons Disease.